Thrombotic thrombocytopenic purpura – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:23:57 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Thrombotic thrombocytopenic purpura – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 A study to evaluate the safety and effectiveness of urokinase, catalytic domain, fused with a single-chain antibody against von Willebrand factor in patients with immune-mediated thrombotic thrombocytopenic purpura. https://clinicaltrials.eu/trial/a-study-to-evaluate-the-safety-and-effectiveness-of-urokinase-catalytic-domain-fused-with-a-single-chain-antibody-against-von-willebrand-factor-in-patients-with-immune-mediated-thrombotic-thrombocytop/ Wed, 29 Apr 2026 15:09:19 +0000 https://clinicaltrials.eu/trial/a-study-to-evaluate-the-safety-and-effectiveness-of-urokinase-catalytic-domain-fused-with-a-single-chain-antibody-against-von-willebrand-factor-in-patients-with-immune-mediated-thrombotic-thrombocytop/ This study focuses on diseases known as Thrombotic Microangiopathies, a group of conditions where small blood vessels become damaged and blocked by tiny blood clots. One specific type of this condition is Immune-Mediated Thrombocytopenic Purpura, a rare disorder where the body’s immune system mistakenly attacks and destroys platelets, which are the cells responsible for helping blood clot. The research aims to evaluate the safety and effectiveness of an experimental drug called TGD001. This medication is a specialized protein designed to target certain factors in the blood that contribute to the formation of these harmful clots.

The treatment involving TGD001 is administered through an intravenous method, which means it is delivered directly into a vein using a solution for injection. During the study, participants will receive the medication to observe how the body reacts and to see if it helps manage the symptoms of the disease. The process involves monitoring how the drug moves through the body and checking for any side effects or changes in blood cell levels over time.

]]> Study on the Safety and Effectiveness of TAK-755 (Apadamtase Alfa) for Patients with Severe Congenital Thrombotic Thrombocytopenic Purpura (cTTP) https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-tak-755-apadamtase-alfa-for-patients-with-severe-congenital-thrombotic-thrombocytopenic-purpura-cttp/ Wed, 29 Apr 2026 15:01:43 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-tak-755-apadamtase-alfa-for-patients-with-severe-congenital-thrombotic-thrombocytopenic-purpura-cttp/ This clinical trial is focused on studying a rare blood disorder called Congenital Thrombotic Thrombocytopenic Purpura (cTTP), also known as Upshaw-Schulman Syndrome or hereditary thrombotic thrombocytopenic purpura. This condition is characterized by the formation of small blood clots throughout the body, which can lead to various health issues. The study is testing a treatment called TAK-755, also known as recombinant ADAMTS13 (rADAMTS13), which is a protein-based medication designed to help manage this condition.

The purpose of the study is to evaluate the long-term safety and tolerability of TAK-755 in patients with severe cTTP. Participants in the study will receive the treatment either as a regular preventive measure or as needed when symptoms occur. The treatment is administered as a powder and solvent for solution, which is then injected either under the skin (subcutaneous use) or directly into a vein (intravenous use). The study aims to monitor any side effects or adverse events that may arise from the treatment over an extended period.

Participants who have previously been involved in related studies or are new to this treatment will be included. The study will continue until 2027, allowing researchers to gather comprehensive data on the effectiveness and safety of TAK-755 in managing cTTP. This research is crucial for understanding how well the treatment works in preventing and managing the symptoms of this rare blood disorder.

]]> Study on Caplacizumab and Immunosuppressive Therapy for Adults with Immune-Mediated Thrombotic Thrombocytopenic Purpura https://clinicaltrials.eu/trial/study-on-caplacizumab-and-immunosuppressive-therapy-for-adults-with-immune-mediated-thrombotic-thrombocytopenic-purpura/ Wed, 29 Apr 2026 14:27:25 +0000 https://clinicaltrials.eu/trial/study-on-caplacizumab-and-immunosuppressive-therapy-for-adults-with-immune-mediated-thrombotic-thrombocytopenic-purpura/ This clinical trial is focused on studying a rare blood disorder called immune-mediated thrombotic thrombocytopenic purpura (iTTP). This condition involves the formation of small blood clots throughout the body, which can lead to a low platelet count and damage to organs. The study will explore the effectiveness and safety of a treatment using a medication called caplacizumab, in combination with immunosuppressive therapy. Immunosuppressive therapy is a treatment that helps reduce the activity of the immune system. The study will not use the usual first-line treatment known as therapeutic plasma exchange, which is a procedure that removes and replaces blood plasma.

The purpose of the study is to evaluate how well the combination of caplacizumab and immunosuppressive therapy works in treating adults with iTTP. Participants in the study will receive caplacizumab, which is given as an injection either into a vein (intravenous) or under the skin (subcutaneous). The study will monitor participants over a period of time to see if they achieve remission, which means the symptoms of iTTP improve or disappear without needing therapeutic plasma exchange. The study will also look at the occurrence of any side effects or adverse events during the treatment period.

Participants will be observed for their response to the treatment, including how quickly their platelet count returns to normal and whether they experience any relapses or worsening of their condition. The study aims to provide valuable information on the potential benefits of using caplacizumab and immunosuppressive therapy for treating iTTP, offering insights into alternative treatment options for this serious condition.

]]>